[Encapsulating peritoneal sclerosis]

Rev Med Chil. 2017 Jan;145(1):41-48. doi: 10.4067/S0034-98872017000100006.
[Article in Spanish]

Abstract

Background: Encapsulating peritoneal sclerosis (EPS) is a complication of peritoneal dialysis (PD) with a low prevalence but high mortality. It is characterized by peritoneal inflammation and fibrosis with subsequent development of intestinal encapsulation. It is associated with a long lapse on PD, frequent episodes of peritonitis, high glucose solution use, and high peritoneal transport status.

Aim: To report the clinical features of patients on PD, who developed EPS.

Material and methods: Review of medical records of 12 patients aged 43 ± 10 years (eight women) who developed EPS.

Results: The mean time spent on PD was 98 months. The main clinical manifestations were abdominal pain in 82% and ultrafiltration failure in 63%. In 92%, there was a history of peritonitis and 75% had high peritoneal transport at the time of diagnosis. The main findings in computed tomography were peritoneal calcification and thickening. There was a biopsy compatible with the diagnosis in 10 cases. Treatment consisted in withdrawal from PD, removal of PD catheter and the use of corticoids and tamoxifen. After withdrawal from PD 50% of patients became asymptomatic. The rest had intermittent abdominal pain and altered bowel movements. Two patients died (17%).

Conclusions: EPS is a serious complication of PD, which should be suspected in any patient with compatible clinical symptoms, long time on PD, multiple episodes of peritonitis and high peritoneal transport profile.

MeSH terms

  • Adult
  • Chile
  • Female
  • Humans
  • Kidney Failure, Chronic
  • Male
  • Middle Aged
  • Peritoneal Dialysis / adverse effects*
  • Peritoneal Fibrosis / etiology*
  • Peritoneal Fibrosis / pathology
  • Peritoneal Fibrosis / therapy
  • Peritonitis / diagnosis*
  • Peritonitis / etiology*
  • Peritonitis / pathology
  • Peritonitis / therapy
  • Retrospective Studies
  • Risk Factors